Oncology

Latest News

Top 5 Most-Read Oncology Content of 2024

December 25th 2024

This year’s most-read oncology content of 2024 includes topics on clinical trials, drug access, vaping and lung cancer, and more!

Most Popular Articles of 2024 in Evidence-Based Oncology

By Mary Caffrey

December 23rd 2024

ICYMI: Highlights From ASCO 2024

By Pearl Steinzor

December 21st 2024

chemotherapy | Image credit: Penn Medicine

The High Cost of Shortages of Low-Cost Chemotherapy

By Interview by Mary Caffrey

December 19th 2024

Leukemia diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Real-World Treatment Sequences and Cost Analysis of cBTKis in CLL

By Pearl Steinzor

December 17th 2024

Join this panel as they discuss treatment for metastatic NSCLC patients without driver mutations.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

October 31st 2017

70-GS Influences Physician Treatment Guidance for Patients With Early Breast Cancer

Jaime Rosenberg

Results of the 70-gene signature assay strongly influence physician's treatment recomendations for patients with early breast cancer who were classified as intermediate risk by the 21-gene assay.

October 30th 2017

Data Challenges Under the Oncology Care Model

Darcie Hurteau

An overview of factors that make the Oncology Care Model performance period data challenging to navigate and use.

October 30th 2017

Global Cancer Burden in Young Adults Differs From That in Other Age Groups

Jaime Rosenberg

A new study found that the global cancer burden in young adults differs from that in younger and older age groups and was more common in women.

October 29th 2017

ARROW Trial: Multiple Myeloma Patients Have Longer PFS With Kyprolis Once-Weekly Regimen

Alison Rodriguez

Results of the Phase 3 ARROW trial revealed that patiehts with refractory multiple myeloma can live up to 3.6 months longer, without their disease worsening, when Kyprolis (carfilzomib) is administered once-weekly at the 70 mg/m2 dose with dexamethasone rather than Kyprolis administered twice-weekly at the 27 mg/m2 dose with dexamethasone, according to Amgen.

October 28th 2017

Study Finds Association Between PARPis Treatment and Severe Hematologic Toxicities

Alison Rodriguez

October 28th 2017

Study Finds Need for Standardization of Immune Checkpoint Inhibitor Assays in NSCLC

Alison Rodriguez

October 27th 2017

Expanding Options for Individualized Treatment of Advanced NSCLC

Christina Mattina

James R. Jett, MD, gave an overview of the advances in diagnosis and treatment of non–small cell lung cancer (NSCLC) during a session at the National Association of Managed Care Physicians Fall Managed Care Forum 2017.

October 27th 2017

Childhood Cancer Survivors Face Job Lock to Keep Insurance Coverage

Alison Rodriguez

Many of survivors of childhood cancer who are now within the prime age for labor force participation are reluctant to make changes in their employment because of access to health insurance, and therefore, job lock is common among this population.

October 26th 2017

Survey: Americans Have High Concerns About Cancer, Low Awareness of Risk Factors

Kelly Davio

Results of the first annual National Cancer Opinion Survey, established by the American Society of Clinical Oncology (ASCO), show that the majority of Americans are unaware of several key risk factors for cancer, and that a minority are taking active steps to reduce their personal risk.

October 25th 2017

Stakeholders Weigh-in on Payment Reform in Cancer Care

Surabhi Dangi-Garimella, PhD

Tuple Health, a healthcare technology startup, interviewed some of the stakeholders participating in value-based care delivery and OCM, to gain their perspective of the state of cancer care and healthcare reform. The results were presented at the Community Oncology Alliance Payer Exchange Summit on Oncology Payment Reform.

October 25th 2017

The Commercial Payer OCM Experience: Year 1

Surabhi Dangi-Garimella, PhD

Representatives from 3 payers who partnered with providers on the Oncology Care Model (OCM) took the stage at Community Oncology Alliance (COA)’s Payer Exchange Summit on Oncology Payment Reform to outline their experience with OCM and how it has differed from other care models.

October 25th 2017

Terrill Jordan: Education and Data Are Key for OCM Success

Education is key to succeed in the Oncology Care Model, but presenting data in a simple format for clinicians to use is also critical, said Terrill Jordan, CEO, of Regional Cancer Care Associates.

October 25th 2017

Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia

Alison Rodriguez

Researchers developed additional guidance for using granulocyte colony-stimulating factors to optimize pegfilgrastim use in clinical practices for patients at risk of chemotherapy-induced febrile neutropenia.

October 25th 2017

Physicians Need Clearer Metrics Before Taking on 2-Sided Risk

Before physicians will be more willing to take on 2-sided risk, there needs to be clearer metrics that the physicians know will be achievable, said Sarah Cevallos, chief revenue cycle officer at Florida Cancer Specialists.

October 25th 2017

The Option Value of Innovative Treatments for Non–Small Cell Lung Cancer and Renal Cell Carcinoma

Julia Thornton Snider, PhD Katharine Batt, MD, MSc Yanyu Wu, PhD Mahlet Gizaw Tebeka, MS Seth Seabury, PhD

Option value is the benefit a therapy provides patients by enabling them to survive to the next innovation.

October 24th 2017

Dr Lucio Gordan: How Practices and Payers Work Together to Implement OCM

The implementation of the Oncology Care Model has brought profound culture changes to how oncologists take care of patients and how they operate practices, explained Lucio Gordan, MD, of Florida Cancer Specialists.

October 24th 2017

Will 2-Sided Risk Be a Reality in OCM?

Kelly Davio

With the Oncology Care Model now in its second year, 3 representatives discussed learnings and how the program can change, as well as incentivizing physicians to accept 2-sided risk, the ability to engage additional payers, and the future of oncology bundle payments.

October 24th 2017

How Has the OCM Evolved? Year 1 Provider Updates

Surabhi Dangi-Garimella, PhD

Participants from 2 oncology community practices—an oncologist–administrator combination—shared their experience with implementing the Oncology Care Model (OCM) with attendees at the Community Oncology Alliance’s Payer Exchange Summit on Oncology Payment Reform, held October 23-24, in Tysons Corner, Virginia.

October 24th 2017

Study: Prophylactic Up-Front Locoregional Surgery Has No Survival Advantage

Jaime Rosenberg

The study found that prophylactic locoregional surgery (LRS) for asymptomatic patients with small intestinal neuroendocrine tumors (SI-NETs) provided no survival advantage compared with delayed LRS.

October 23rd 2017

Increased Insurance Coverage Seen Under the ACA for Patients With Cancer

Jaime Rosenberg

A new study has found that uninsurance rates declined the most in patients with distant disease and with lung and bronchial cancer. Hispanic patients also saw a large decrease in uninsurance rates.

October 21st 2017

Podcast: This Week in Managed Care - Bipartisan ACA Deal and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

October 20th 2017

This Week in Managed Care: October 20, 2017

This week, the top managed care news included the bipartisan deal to stabilize the Affordable Care Act's insurance markets; coverage from the Academy of Managed Care Pharmacy 2017 Nexus; and a plan to reduce clinician burnout at the computer.

October 19th 2017

Kite Pharma's CAR T-Cell Treatment Approved, Cheaper Than Tisagenlecleucel

Surabhi Dangi-Garimella, PhD

Axicabtagene ciloleucel (Yescarta) has been approved to treat adult patients with diffuse large B-cell lymphoma who have not responded to or who have relapsed after at least 2 other kinds of treatment.

October 18th 2017

PD-1 Inhibitor Doubled Survival in Treatment-Naive Patients With mNSCLC

Surabhi Dangi-Garimella, PhD

The 2-year follow up results from the Keynote-024 trial were presented at the 18th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Yokohama, Japan.

October 18th 2017

Increasing Levels of CD8+ TILs Prolong Survival in High-Grade Serous Ovarian Cancer

Jaime Rosenberg

There is a relationship between CD8+ tumor infiltrating lymphocytes (TILs) and high-grade serous ovarian carcinoma (HGSOC) survival, according to a new study published in JAMA Oncology.

October 17th 2017

PBMs: Their Role, the Problems, and How Practices Can Work With Them

Ray Bailey, RPh Ricky Newton, CPA

October 17th 2017

Positive Quality Interventions: An Innovative Platform for Oncology Practice Collaboration

Joshua Nubla, PharmD Neal Dave, PharmD Michael Reff, RPh, MBA

An in-depth look into a nationwide collaborative initiative to standardize and improve oncology dispensing practices for the benefit of patient/provider education, adherence, and overall care.

October 17th 2017

Looking Ahead at the Specialty Drug Pipeline After an Active Year of Approvals

Christina Mattina

Aimee Tharaldson, PharmD, of Express Scripts kicked off the Academy of Managed Care Pharmacy (AMCP) 2017 Nexus, held October 16-19 in Dallas, Texas, with a presentation on the pipeline of specialty pharmaceuticals in development.

October 17th 2017

UK Patients With Head and Neck Cancer Will Soon Have Access to Nivolumab

Jaime Rosenberg

The immunotherapy drug, made by Bristol-Myers Squibb, is recommended for use within the Cancer Drug Fund.

October 16th 2017

Trends in Hospital–Physician Integration in Medical Oncology

Jeffrey D. Clough, MD, MBA Michaela A. Dinan, PhD Kevin A. Schulman, MD

The authors used Medicare claims data to examine trends in hospital–physician integration in high-volume specialties, including medical oncology.

...

59 60 61 62 63 64 65 66 67

...

181 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions